II. Pathophysiology: Cancers most prone to metastasize to long bones
- Most common cancers with bony metastases
- Other common cancers with bony metastases
III. Symptoms
- Localized bone pain
- Dull, Intermittent pain
- Night pain and rest pain is pathognomonic for Cancer Pain
- Pain despite lack of injury history
- Weight-bearing related pain may predict Fracture
IV. Exam
- Focus on identifying primary cancer if not known
V. Imaging
-
General
- Multiple lesions are hallmark of metastatic Bone Cancer
- Plain film XRay: Indicated as first-line study
- Efficacy
- Test Sensitivity: Low (requires 50% Trabecular Bone loss before evident)
- Test Specificity: Highest among imaging studies
- Findings
- Lytic lesions: Lung Cancer, Thyroid Cancer, Renal Cancer
- Blastic lesions: Prostate Cancer
- Other cancers are mixed-type (lytic and blastic)
- Efficacy
- Bone Scan
- Indications
- Identify additional metastatic cancer sites
- Evaluate bone pain in patient with known primary tumor
- Efficacy
- Test Sensitivity: High
- Identifies bony lesions down to 2 mm
- Identifies metastatic lesions up to 18 months before plain film xray
- Test Specificity: Low
- Test Sensitivity: High
- Indications
- Computed Tomography (CT Scan)
-
Magnetic Resonance Imaging (MRI)
- Indications
- Evaluate spinal lesions
- Evaluate soft tissue spread of bony lesions
- Evaluate Bone Marrow destruction
- Indications
- References
VI. Labs: Adjust based on primary tumor suspected
-
Serum Protein Electrophoresis (SPEP)
- Evaluate for Multiple Myeloma
-
Complete Blood Count with Platelets
- Evaluate for Anemia and Thrombocytopenia
- Serum Creatinine
-
Serum Calcium
- Evaluate for Hypercalcemia
- Serum Alkaline Phosphatase
- Prostate Specific Antigen (PSA)
VII. Labs: Biopsy Indications
- Confirm metastatic cancer in known primary cancer
- Evaluate bone tissue for advance lab testing (e.g. immunohistochemical stains)
- Evaluate bony lesion where primary tumor is unknown
- Rarely identifies the primary tumor
VIII. Management
- Pain management
- Narcotic Analgesics
- NSAIDs
- Corticosteroids if nerve impingement from tumor mass
- Suppression of tumor growth or mass effect
- Calcitonin does not appear effective in reducing pain, morbidity, or cancer progression
- Bisphosphonates (started when bony metatastases are diagnosed)
- Pamidronate (Aredia) 90 mg IV every 3 weeks or
- Zoledronic acid (Zometa)
- Chemotherapy
- Cancer-specific agents
- Hormonal therapy: Breast Cancer, Prostate Cancer
- Radiotherapy or Radiopharmacotherapy
- Surgical intervention indications
- Impending pathologic Fracture
- Decrease pain
- Improve morbidity and function